Magi Astrology--Financial Astrology

FINANCIAL ASTROLOGY

First Trade Date for Immunex Corp.

Company Name	First Trade Date (yyyy-mm-dd)
Immunex Corp.	1983-07-01

Company Name	Symbol
Immunex Corp.	IMNX
History and Business of Company (this information may include date of incorporation)
Immunex Corp. (IMNX) is dedicated to developing immune system science to protect human health. IMNX applies its scientific expertise in the fields of immunology, cytokine biology, vascular biology, antibody-based therapeutics and small molecule research to discover new targets and new therapeutics for treating rheumatoid arthritis, asthma and other inflammatory diseases, as well as cancer and cardiovascular diseases. The company's products are marketed in the U.S. and are available by prescription only. Many of IMNX's biotechnology products and products under development are recombinant analogs of cytokines and cytokine receptors. Cytokines are protein messengers that coordinate the functions of immune cells, which are white blood cells, and other types of cells and tissues. IMNX has developed recombinant cytokine products capable of expanding and activating these immune cell populations, all of which must interact to provide a normal immune response. IMNX's product revenues come from products in two major therapeutic classes: anti-inflammatory and specialty therapeutics, principally oncology and multiple sclerosis. Enbrel is a soluble tumor necrosis factor, or TNF, receptor that inhibits the binding of TNF to TNF cell surface receptors, resulting in a significant reduction in inflammatory activity in rheumatoid arthritis. Rheumatoid arthritis, or RA, is a serious, chronic autoimmune disorder that causes the body's immune system to attack the lining of the joints, and can lead to joint deformity or destruction, organ damage, disability and premature death. Revenues from sales of Enbrel were $652.4 million, or approximately 76% of total revenue, in 2000, $366.9 million, or approximately 68% of total revenue, in 1999 and $12.7 million, or approximately 5% of total revenue, in 1998. The company's other products include Leukine, which helps to increase the number and improve the function of specific types of white blood cells; Novantrone, a compound similar to doxorubicin and idarubicin, two chemotherapeutic agents frequently used to treat some cancers, but with a molecular change that results in less damage to the heart; Thioplex, which is approved for the palliative treatment of a wide variety of tumor types; Amicar, used to decrease bleeding in specific surgical procedures and other medical situations; Methotrexate sodium injectable, used in the treatment of a number of neoplastic, or tumor, diseases; and Leucovorin calcium, used in methotrexate rescue therapy and in modulation of 5-fluorouracil drug therapy in advanced colorectal cancer. INCORPORATED in Delaware Dec. 10, 1992, as Lederle Oncology Corp. (Successor), a wholly owned subsidiary of Lederle Parenterals, Inc. (LPI), in turn wholly owned by American Cyanamid Co. (Cyanamid), and on June 1, 1993, Successor merged Immunex Corp. (Predecessor) and adopted Predecessor's title. Immediately prior to the merger, all Common stock of Successor held by Cyanamid and LPI were converted into that number of Common shares equal to 53.5% of the total number of shares of Successor. In the merger, each outstanding Common share of Predecessor was converted into the right to receive one Common share of Successor and $21 cash; and Cyanamid contributed its oncology business in the U.S. and Canada and $350,000,000 cash to Successor. In late 1994, American Home Products Corp. acquired all Common stock of Cyanamid. Predecessor was incorporated in Delaware May 7, 1987 and on July 23, 1987 merged its former parent share-for-share. Former parent was incorporated in Washington July 13, 1981. OFFICE- 51 University Street, Seattle, WA 98101 (Tel.: 206-587-0430). Fax - 206-587-0606. WEBSITE-http://www.immunex.com.

IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.